pre-IPO PHARMA

COMPANY OVERVIEW

G3 Pharmaceuticals, Inc. is a privately held biopharmaceutical company located in Burlington, MA. The company was founded by thought leaders in the fields of galectin-3 biology, cardiovascular pharmaceutical development, and carbohydrate drug synthesis and manufacturing. The founders have played a material role in advancing the understanding of the role of galectin-3 in cardiovascular and renal disease, and in the exploration of pharmaceutical inhibition of galectin-3 by carbohydrate compounds. Publications related to this galectin-3 research by the founders have been cited over 2,000 times, illustrating the importance of these contributions to advancing the science that forms the foundation of G3 Pharmaceuticals.


LOCATION

  • Lexington, MA, USA

  • THERAPEUTIC AREAS

  • Cardiovascular Disease

  • WEBSITE

    https://www.g3pharma.com


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS



    PRESS RELEASES


    Dec 19, 2019

    G3 Pharmaceuticals and Nestlé Health Science To Pursue Development of Galectin-3 Inhibitors


    Oct 30, 2018

    G3 Pharmaceuticals Signs Exclusive License and Option Agreement for Treating Diastolic Heart Failure (HFpEF) by Inhibiting Galectin-3.


    Sep 14, 2017

    G3 Pharmaceuticals to Pursue a Novel Class of Cardiovascular Pharmaceuticals


    For More Press Releases


    Google Analytics Alternative